NCT02108548终止1 期
A Phase 1 Ascending Single and Multiple Oral Dose Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects, Including a Food Effect Cohort
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 89
- 试验地点
- 1
- 主要终点
- Part 1 and 2: Safety assessed by adverse events, vital signs, laboratory tests, electrocardiogram (ECGs), collagen and adenosine diphosphate (ADP)-induced platelet aggregation, and gastrointestinal (GI) safety assessments (Part 2 only)
研究概览
简要总结
The purpose of this study is to evaluate the safety and tolerability of single and multiple ascending oral doses of ASP7657 in healthy subjects.
详细描述
Subjects are healthy males aged 18 to 55 years of age (inclusive) (Parts 1 and 2, young cohorts) or the subject is an elderly healthy male or female subject aged 65 years or more (Part 2, elderly cohort).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject has a body mass index (BMI) range of 18.5 to 30.0 kg/m2, inclusive. The subject weighs at least 50 kg [screening]
- •Subject agrees to undergo gastro-duodenoscopy (GDS) if needed (Part 1: in case of gastrointestinal (GI) complaints/positive fecal blood test; Part 2: all subjects)
排除标准
- •Subject has known or suspected hypersensitivity to ASP7657 or naproxen, or any components of the formulation used
- •Subject has any of the liver function test above the upper limit of normal (ULN)
- •Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
- •Subject has any history or evidence of any clinically significant cardiovascular, GI, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy
- •Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (noncutaneous) infection within 1 week prior to day of admission
- •Subject has any clinically significant abnormality
- •Subject has a pulse < 40 or > 90 beats per minute (bpm); mean systolic blood pressure (SBP) > 140 mmHg; mean diastolic blood pressure (DBP) > 90 mmHg (measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically) at day -
- •(For elderly subjects the following criteria apply: DBP > 100 mmHg, SBP > 160 mmHg [day of admission])
- •Subject has a mean QT interval corrected for heart rate using Fridericia's formula (QTc(F)) of > 430 ms (for males) and > 450 ms (for females).
- •Subject uses any prescribed or nonprescribed drugs (including nonsteroidal anti-inflammatory drugs (NSAIDs), anti-coagulants, vitamins, natural and herbal remedies, e.g., St. John's wort) in the 2 weeks prior to first study drug administration, except for occasional use of paracetamol (up to 2 g/day)
- •Subject has a history of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the clinical unit.
- •Subject has a history of drinking > 21 units (males) or > 14 units (females) of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) within 3 months prior to admission to the clinical unit or the subject tests positive at screening or clinical admission for alcohol or drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates)
- •Subject uses any drugs of abuse within 3 months prior to admission to the clinical unit
- •Subject has significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission
- •Subject uses any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months prior to admission to the clinical unit regularly
- •Subject has a positive serology test for hepatitis B surface antigen (HBsAg), anti-hepatitis A virus (HAV) (immunoglobulin [Ig]M), anti-hepatitis C virus (HCV) or anti-human immunodeficiency virus (HIV) 1+2
- •Subject has a positive H.Pylori test at screening
- •Subject has a positive fecal blood test at screening
- •Subject participated in any interventional clinical study or has been treated with any investigational drugs within 90 days or 5 half-lives whichever is longer, prior to the initiation of screening
- •Subject is an employee of the Astellas Group or Clinical Research Organization involved in the study
- •Subject has a history of peptic ulceration or significant dyspepsia
- •Subject uses concomitant medication associated with peptic ulceration, or presence of other risk factors for peptic ulceration
- •Subject, if non-elderly, has endoscopic evidence of inflammation, ulceration, erosion, mucosal hemorrhage, or active bleeding in esophagus, stomach, pyloric channel or duodenum, and a mucosal grading scale score > 2 for both stomach and duodenum at baseline visit (Part 2 healthy young male cohorts)
研究组 & 干预措施
Part 1: ASP7657 Single Ascending Dose - Food Effect
Experimental
干预措施: ASP7657 (Drug)
Part 2: Naproxen
Active Comparator
干预措施: naproxen (Drug)
Part 1: ASP7657 Single Ascending Dose
Experimental
干预措施: ASP7657 (Drug)
Part 1: Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Part 2: ASP7657 Multiple Ascending Dose
Experimental
干预措施: ASP7657 (Drug)
Part 2: ASP7657 Multiple Ascending Dose Elderly
Experimental
干预措施: ASP7657 (Drug)
Part 2: Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Part 1 and 2: Safety assessed by adverse events, vital signs, laboratory tests, electrocardiogram (ECGs), collagen and adenosine diphosphate (ADP)-induced platelet aggregation, and gastrointestinal (GI) safety assessments (Part 2 only)
时间窗: Up to Day 20
次要结局
- Part 2: PD profile of plasma renin activity and aldosterone(Days -1, 7, and 14)
- Part 2: PK profile of ASP7657 after first dose in plasma: tlag, tmax, Cmax and AUC from the time of dosing to 24 hours postdose (AUC24)(Day 1)
- Part 2: PD of urine electrolytes: amount excreted over 24 hours (Ae24)(Days -1 and 14)
- Part 1: PK profile of ASP7657 in urine: Aelast, Aeinf, Aelast%, Aeinf%, CLr(Day 1)
- Part 1: Pharmacodynamics (PD) profile of tumor necrosis factor alpha (TNF-α) in whole blood: maximum response (Rmax), area under the dose-response curve (AURC), and time to reach maximum response (tmax,R)(Day 1)
- Part 1: PD in urine: Total urine volume over 24 hours(Day -1 and Day 1)
- Part 2: PK profile of ASP7657 after last dose in plasma: AUC from the time of dosing to the start of the next dosing interval (AUCtau), tmax, Cmax, t ½, Vz/F, CL/F, Accumulation ration (Racc), peak-trough ratio (PTR)(Day 14)
- PK profile of ASP7657 after last dose in urine: Aetau, (Aetau%), and CLr(Day 14)
- Part 1: Pharmacokinetics (PK) profile of ASP7657 after a single dose in plasma: AUCinf, AUClast, tlag, tmax, Cmax, t 1/2, Vz/F, CL/F(Day 1)
- Part 2: PK of ASP7657 in plasma: concentration immediately prior to dosing at multiple dosing (Ctrough)(Days 2, 4, 6, 8, 10 and 12)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food EffectHealthy VolunteersNCT04077879Astellas Pharma Global Development, Inc.97
终止
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205Healthy SubjectsPharmacokinetics of ASP2205NCT02314793Astellas Pharma Europe B.V.93
已完成
1 期
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With SchizophreniaSchizophreniaNCT02720263Astellas Pharma Global Development, Inc.48
已完成
1 期
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive DisorderMajor Depressive DisorderNCT01670279Otsuka Pharmaceutical Development & Commercialization, Inc.18
已完成
1 期
Study Evaluating the Pharmacokinetics of HCV-796 in Healthy Japanese MenHealthyNCT00385190Wyeth is now a wholly owned subsidiary of Pfizer24